Company Statera Biopharma, Inc.

Equities

STAB

US8575611046

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.0007 ^USD	0.00%		0.00%	+16.67%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Number of employees: 46

USD in Million	2020	Weight	2021	Weight	Delta
Toll-like Receptors 100.0 %	0	100.0 %	1	100.0 %	+465.54%

USD in Million	2020	Weight	2021	Weight	Delta
United States 100.0 %	0	81.2 %	1	100.0 %	+596.47%

Managers	Title	Age	Since
Yakov Kogan FOU	Founder	50	03-06-04
Andrei V. Gudkov FOU	Founder	66	03-06-04
Michael Handley CEO	Chief Executive Officer	52	21-07-26
Christopher Zosh DFI	Director of Finance/CFO	48	14-05-31
Allie Lopez CTO	Chief Tech/Sci/R&D Officer	-	20-06-30
James Mendolera CTO	Chief Tech/Sci/R&D Officer	-	21-01-31
Robert W. Buckheit CTO	Chief Tech/Sci/R&D Officer	63	21-07-26
George Wagner LAW	General Counsel	-	-
Curt Dewitz PRN	Corporate Officer/Principal	-	20-02-29
Todd Headley PRN	Corporate Officer/Principal	-	20-12-31

Members of the board	Title	Age	Since
John A. Kallassy BRD	Director/Board Member	59	22-09-01
Uday Saxena BRD	Director/Board Member	66	22-06-16
Michael Handley CEO	Chief Executive Officer	52	21-07-26
C. Satish Chandran BRD	Director/Board Member	68	22-02-23
Selby Blake Hawley BRD	Director/Board Member	59	22-06-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,416,038	71,416,038 ( 100.00 %)	0	100.00 %

Name	Equities	%	Valuation
Tucker Asset Management LLC 0.001400 %	1,000	0.001400 %	1 $
Manulife Investment Management Ltd. 0.000223 %	159	0.000223 %	0 $
AlphaStream Portfolios, Inc. 0.000062 %	44	0.000062 %	0 $

Statera Biopharma, Inc.

4333 Corbett Drive Suite 1082

80525, Fort Collins

+888 613 8802

http://www.staterabiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
STATERA BIOPHARMA, INC.	+16.67%	50.81K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research